×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ACAD – acadia pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ACAD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/12
08:36 am
acad
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]
12/12
08:00 am
acad
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
Neutral
Report
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
12/11
08:44 am
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.
12/6
12:31 pm
acad
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]
Medium
Report
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]
12/6
10:24 am
acad
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection [Yahoo! Finance]
Medium
Report
Assessing Acadia Pharmaceuticals (ACAD) Valuation After Strong Q3 Results and Extended NUPLAZID Patent Protection [Yahoo! Finance]
12/4
06:33 pm
acad
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
Low
Report
Buy Acadia Pharmaceuticals For Daybue/Nuplazid Stability And Pipeline Optionality [Seeking Alpha]
12/4
01:01 pm
acad
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/3
09:42 am
acad
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
Low
Report
Acadia to pivot to Alzheimer's psychosis pipeline, accd to Wall Street analysts [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:05 pm
acad
acadia pharmaceuticals inc.
BEAT
Report
-3.0%
acadia pharmaceuticals inc.
8/6/2025
04:05 pm
acad
acadia pharmaceuticals inc.
BEAT
Report
2.5%
acadia pharmaceuticals inc.
5/7/2025
04:05 pm
acad
acadia pharmaceuticals inc.
BEAT
Report
14.3%
acadia pharmaceuticals inc.
2/26/2025
04:05 pm
acad
acadia pharmaceuticals inc.
BEAT
Report
1.8%
acadia pharmaceuticals inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/19
06:01 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Kihara James
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Kihara James
11/19
06:01 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Schneyer Mark C.
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Nov 17 Filed by: Schneyer Mark C.
11/14
08:17 am
acad
Form SCHEDULE 13G/A ACADIA PHARMACEUTICALS Filed by: RTW INVESTMENTS, LP
Medium
Report
Form SCHEDULE 13G/A ACADIA PHARMACEUTICALS Filed by: RTW INVESTMENTS, LP
11/12
06:00 pm
acad
Form 4 ACADIA PHARMACEUTICALS For: Nov 10 Filed by: Daly James M
Low
Report
Form 4 ACADIA PHARMACEUTICALS For: Nov 10 Filed by: Daly James M
11/10
06:00 pm
acad
Form 144 ACADIA PHARMACEUTICALS Filed by: Daly James M
Medium
Report
Form 144 ACADIA PHARMACEUTICALS Filed by: Daly James M
11/6
06:02 am
acad
Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30
Medium
Report
Form 10-Q ACADIA PHARMACEUTICALS For: Sep 30
11/5
04:14 pm
acad
Form 8-K ACADIA PHARMACEUTICALS For: Nov 05
Medium
Report
Form 8-K ACADIA PHARMACEUTICALS For: Nov 05
11/3
04:23 pm
acad
Form 8-K ACADIA PHARMACEUTICALS For: Oct 28
Low
Report
Form 8-K ACADIA PHARMACEUTICALS For: Oct 28
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
9/9
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis
61.4%
7/31 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.460 ActVsEst 0.080 - Beat 16.6%
12/4 Acadia Pharma's psychosis drug proven better than placebo in dementia patients [Reuters] 10.9%
11/11 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019 9.3%
9/14 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.0%
10/19 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.1%
4/2 Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha] 6.8%
5/3 ACADIA -3.5% after 40.2M-share shelf registration [Seeking Alpha] 6.7%
9/9 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Piper Jaffray Companies from $35.00 to $56.00. They now have an "overweight" rating on the stock. 6.5%
3/3 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome 6.1%
7/31 Q2/2019 6/30/2019 EPS -0.380 ZacksConsensus -0.460 ActVsEst 0.080 - Beat 16.6%
12/4 Acadia Pharma's psychosis drug proven better than placebo in dementia patients [Reuters] 10.9%
11/11 ACADIA Pharmaceuticals to Host Investor Event and Webcast From Clinical Trials on Alzheimer’s Disease (CTAD) Meeting on December 4, 2019 9.3%
9/14 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 9.0%
10/19 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 8.1%
4/2 Acadia Pharmaceuticals: Multiple Growth Catalysts Ahead [Seeking Alpha] 6.8%
5/3 ACADIA -3.5% after 40.2M-share shelf registration [Seeking Alpha] 6.7%
9/9 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at Piper Jaffray Companies from $35.00 to $56.00. They now have an "overweight" rating on the stock. 6.5%
3/3 ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome 6.1%
TOP News Decliners
9/9
Form 8-K ACADIA PHARMACEUTICALS For: Sep 09
-22.3%
7/22 Acadia's schizophrenia treatment fails to meet main goal of late-stage study [Reuters] -14.4%
1/13 Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 -9.1%
8/31 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.7%
5/1 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.4%
9/11 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -7.3%
12/6 Form 4 ACADIA PHARMACEUTICALS For: Dec 05 Filed by: DAVIS STEPHEN -6.4%
2/27 ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.3%
9/25 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 -6.0%
3/5 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.6%
7/22 Acadia's schizophrenia treatment fails to meet main goal of late-stage study [Reuters] -14.4%
1/13 Form 8-K ACADIA PHARMACEUTICALS For: Jan 13 -9.1%
8/31 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -8.7%
5/1 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. -7.4%
9/11 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) was given a new $60.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -7.3%
12/6 Form 4 ACADIA PHARMACEUTICALS For: Dec 05 Filed by: DAVIS STEPHEN -6.4%
2/27 ACADIA Pharmaceuticals Inc. (ACAD) CEO Steve Davis on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.3%
9/25 ACADIA Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on October 2, 2019 -6.0%
3/5 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) is now covered by analysts at Citigroup Inc. They set a "buy" rating on the stock. -5.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: